Kornimate/medical-research-clean huggingface dataset:
urinary cytokine levels as a prognostic marker for kidney scarring after pyelonephritis

Conditions: Kidney Scarring Post-Febrile UTI

Summary: the prevalence of kidney scarring after uti is approximately 5-57%. utis are caused mainly by bacteria that cause local and systemic immunological reaction that are accompanied by cytokines. these cytokines are a main factor in the inflammatory process. they are produced by leukocytes, macrophages, fibroblasts, endothelial cells and epithelial cells in the kidney tissue. interleukin 6 and 8 (il-6 il-8) were found in high levels in the urine of children and adults who suffer from utis. other studies on animals have found a relationship between inflammatory reaction and scarring in the kidney. we hypothesize that we will find a similar relationship between the level of il-6, il-8 in the urine during acute pyelonephritis in children and the probability of kidney scarring.


Eligibility criteria:
inclusion criteria: * children aged 0-7 * first episode febrile uti exclusion criteria: * recurrent uti
non-significant risk study of sebacia microparticles in the treatment of facial acne vulgaris

Conditions: Acne Vulgaris

Summary: prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating sebacia microparticles (sm) with nd:yag laser in facial inflammatory acne vulgaris


Eligibility criteria:
inclusion criteria: * mild to moderate acne vulgaris * at least 15 inflammatory acne lesions * skin phototype i - iii * able to understand and comply with study requirements exclusion criteria: * severe acne vulgaris * nodulocystic acne * ongoing use of medications and/or treatments for acne * new hormone regimen (used for less than 12 weeks) * significant medical or mental health condition
enhancing cognitive training through exercise after a first schizophrenia episode

Conditions: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder

Summary: this is a randomized controlled 6-month trial of the efficacy of a novel intervention combining neuroplasticity-based cognitive training with aerobic exercise, compared to the same systematic cognitive training alone. the primary treatment targets are overall cognitive deficit level and independent living skills. the investigators hypothesize that combining neuroplasticity-based computerized cognitive training and neurotrophin-enhancing physical exercise will produce large cognitive and functional improvements, even relative to cognitive training alone. adding aerobic exercise to a cognitive training program will have the additional benefit of helping to ameliorate medication side effects, reduce the risk for developing metabolic syndrome, and help to prevent the deterioration in physical health that usually follows the onset of schizophrenia and its pharmacologic treatment. the investigators target the period shortly after a first episode of schizophrenia to maximize the generalization of cognitive improvement to functional outcome, before chronic disability is established.

the cognitive training and exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. the first 12 weeks involves neurocognitive training, using auditory training exercises from posit science brain hq. the second 12 weeks involves social cognitive training, using the posit science socialville modules. aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder. a weekly one-hour bridging skills group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.

Eligibility criteria:
inclusion criteria: 1. a first episode of a psychotic illness that began within the past two years; 2. a diagnosis by diagnostic and statistical manual of mental disorders of schizophrenia, schizoaffective disorder, mainly depressed type, or schizophreniform disorder; 3. between 18 and 45 years of age; 4. sufficient acculturation and fluency in the english language to avoid invalidating research measures of thought, language, and speech disorder or of verbal cognitive abilities; and 5. residence within commuting distance of the aftercare research program at the university of california, los angeles. exclusion criteria: 1. evidence of a known neurological disorder (e.g., epilepsy) or significant head injury; 2. evidence of alcohol or substance use disorder within the six months prior to the first episode and evidence that substance abuse triggered the psychotic episode or makes the schizophrenia diagnosis ambiguous; 3. mental retardation, i.e. premorbid intelligence quotient less than 70.

Keywords: cognitive training aerobic exercise neurotrophic factors randomized controlled trial
the investigation of the pre-movement facilitation of agonist-antagonist muscles and the effect of the feedforward rehabilitation in individuals with hypermetria

Conditions: Spinocerebellar Atrophy (SCA)

Summary: in individuals with spino-cerebellar atrophy (sca), the delayed onset of antagonist muscle firing has been reported to be the cause of hypermetria. hypermetria is a common deficit in individuals with spino-cerebellar atrophy sca when they perform ballistic goal-directed movement. based on the previous studies, ballistic goal-directed movements are controlled by a triphasic pattern of agonistic and antagonistic muscle activation. the origin of the emg pattern is a central program, whereas the delayed onset of antagonistic muscle firing has been reported to be the cause of hypermetria. to develop a therapy method, the difference in temporal pattern and intensity of supraspinal excitability of agonist and antagonist bursts between healthy adults and individuals with sca when performing rapid and slow goal-directed movements should be further investigated. traditional rehabilitations of individuals with cerebellum lesion were limited to improve the functional performance of movement. since the deficits of the goal-directed movement are at pre-movement programming, only feedforward training will be possible to re-establish an appropriate program. previous showed that peripheral stimulation resulted in a facilitation of motor cortex. our group also found that this facilitation in individuals with sca was similar to the ones without sca. therefore, it is possible to adjust the control pattern of supraspinal excitability of agonist and antagonist busts of sca patient with passively providing electrical stimulation contains normal control pattern of healthy human. the present study sought to investigate the difference in temporal pattern and intensity of supraspinal excitability of agonist and antagonist bursts between healthy adults and individuals with sca when performing rapid and slow goal-directed movements.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of spinocerebellar ataxia

Keywords: pre-movement facilitation fast goal directed movement triphasic emg pattern temporal electrical stimulation, spinocerebellar ataxia
feasibility study to assess the scan, fit and print process for the aveera "patient matched" cpap mask

Conditions: Obstructive Sleep Apnea

Summary: feasibility study to assess the scan, fit and print process for the aveera "patient matched" cpap mask

1. assess the process of scan, fit and print 2. subjective/objective assessment of fit of the aveera during the 2 week use for leaks and comfort 3. ethnographic insights into the user experience of the scan, fit, print process.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * both genders * currently prescribed fixed pressure cpap or apap for the treatment of osa * currently cpap pillows and nasal mask users * patients who are adherent as defined by conventional standards (i.e. 4 hours per night/70% of the nights) exclusion criteria: * unwilling to wear the aveera * concern about privacy of data * pregnant * full face mask user * any medical condition deemed by the investigator to pose an issue with the subject's participation. * upper limit of cpap pressure of ≥ to 15 cm h20 or apap a upper limit pressure setting of ≥17cm h2o * requires the use of supplemental oxygen
type ii supracondylar fractures in children

Conditions: Type II Supracondylar Fractures

Summary: supracondylar fractures are the most common elbow fractures in children. in the current orthopedic literature crossed pinning and lateral-only entry techniques are co-gold standards of operative treatment. the crossed pinning technique has been shown to be biomechanically superior especially under torsional loading but has a higher incidence of iatrogenic injury to the ulnar nerve. all studies comparing these techniques to date have been either biomechanical or retrospective in nature. a randomized, controlled, prospective study comparing these two popular techniques has not been performed. the purpose of this study is to prospectively evaluate the amount of displacement incurred when treating type iii supracondylar humerus fractures in children with crossed pinning versus lateral-entry only technique. overall complication rate, loss of reduction, iatrogenic neurovascular injury, and pin tract infection rates between the two cohorts will be evaluated. the study population will comprise all patients less than ten years of age presenting to scottish rite hospital during the study period with a type iii supracondylar fracture managed by the children's healthcare of atlanta orthopedic group. all patients will be randomized to one specific treatment arm based on surgeon preference established at the onset of the study. the hypothesis to be tested is that no difference in amount of displacement or overall complication rate is present between these two techniques. radiographic parameters measured pre-operatively, immediately post-operatively and four weeks post-operatively will be quantitatively evaluated and compared. chart reviews to determine complications during the treatment period will be made. pre-study power analysis and post-study statistical analysis will be performed.

pre-operative consent forms for study participation will be reviewed with all families at the time of the pre-operative visit. screening will be performed at the time of evaluation in the emergency room. patients will be assigned to a particular group based on the surgeon that performs their surgery. each surgeon at the onset of the study will commit to one technique of operative management with the understanding that this technique may be abandoned by the surgeon in any case where it is felt to be inadequate. changing technique will be considered a failure of the technique. data regarding the treatment will be collected from the chart and x-rays at the time of treatment and at follow up visits in the orthopedic office.

Eligibility criteria:
inclusion criteria: * closed, gartland's type iii extension supracondylar humerus fractures requiring closed reduction and pinning. exclusion criteria: * age greater than ten * open fracture * need for open reduction in the operating room * need for vascular repair of the ipsilateral extremity

Keywords: type ii supracondylar fracture orthopaedics
antegrade double-j stent placement for the treatment of malignant obstructive uropathy

Conditions: Urologic Neoplasms

Summary: ureteral double- j stent is usually inserted by retrograde approach for the treatment of obstructed upper urinary tract. the antegrade approach, can a suitable alternative in certain situations without the need for general or spinal anesthesia. the present study demonstrates the indications, success rate, and complications of this approach in the treatment of malignant obstructive uropathy.

data of consecutive patients in whom antegrade ureteral stent¬ing was performed between january 2013 and february 2020 were retrospectively analysed using patient records and radiology reports. a total of 174 patients (sexe ratio = 0.51, age range 9-91 years; mean age, 54 years) were included in the study. ureteral obstruction was caused by bladder cancer (n=92), uterin cancer (n=31), prostate cancer (n=28), colorectal cancer (n= 15) and retroperitoneal tumor (n= 8) (table 1).

Eligibility criteria:
inclusion criteria: * malignant uropathy obstruction exclusion criteria: * benign uropathy obstruction
turkish version of the mini-bestest: transcultural adaptation and validation study in stroke patients

Conditions: Stroke; Balance; Distorted

Summary: "mini-bestest (turkish version)", "berg balance test", "timed up and go test" and "functional reach test" will be used for balance measurement in patients and the correlation of the mini-best with these tests will be checked.

the first part of the study is the turkish translation of mini-bestest. after the translation process, "mini-bestest (turkish version)", "berg balance test", "timed up and go test" and "functional reach test" will be used for balance measurement in patients and the correlation of the mini-best with these tests will be checked. all tests will be applied by 2 researchers on the same day, 2 times with 10 minutes intervals.

Eligibility criteria:
inclusion criteria: 1. chronic stroke patients 2. patients who can execute commands 3. patients who are ambulatory enough to complete most balance tasks 4. patients participating in the study voluntarily exclusion criteria: 1. acute stroke patients 2. patients who cannot execute commands 3. non-ambulatory patients 4. pediatric patients and pregnant patients

Keywords: balance stroke validity reliability
ottawa nutritional guidelines for nausea and vomiting

Conditions: Nausea Gravidarum

Summary: effect of implementing ottawa nutritional guidelines on the course of nausea and vomiting during pregnancy (a randomized control trial)

studying the effect of implementing ottawa nutritional guidelines on the course of nausea and vomiting during pregnancy (a randomized control trial) using no pharmacological agents and life style modification in addition to acupressure to treat nausea and vomiting of pregnancy

Eligibility criteria:
inclusion criteria: 1. primigravida 2. gestational age of 7-13 weeks 3. singleton pregnancy 4. having a score of 7-12 on the (puqe 24) 5. can read and write 6. having phone number 7. not receiving medications for reducing nvp, except for vitamin b6 8. wanted pregnancy. exclusion criteria: 1. subject's unwillingness to continue the study 2. occurrence of obstetric complications during the study 3. hyper-emesis gravidarum 4. having physical or mental disorders 5. having oral/speech impairments 6. having assisted reproductive techniques for the present pregnancy 7. having two consecutive miscarriages before the current pregnancy 8. old primigravida 9. narcotic use or alcohol drinking 10. and subjects who will show signs and symptoms of hyperemesis gravidarum during the study will be dropped out and referred to medical care.
comparing the efficacy and safety of finerenone and spironolactone in the treatment of primary aldosteronism

Conditions: Primary Aldosteronism; Hypertension

Summary: primary aldosteronism (pa) is thought to be the most common secondary endocrine form of hypertension. compared with patients with essential hypertension with similar blood pressure, patients with pa have significantly higher atrial fibrillation, myocardial infarction, heart failure, stroke, deterioration of renal function and all-cause mortality. therefore, early and systematic implementation of effective surgical or medical treatment is essential to prevent or reverse the excess vascular events and mortality of these patients. the patients with bilateral pa were mainly treated with mineralocorticoid receptor antagonists (mras). the mra spironolactone is effective at lowering bp and reversing the harmful metabolic consequences, but its use is limited by adverse effects such as gynaecomastia, mastodynia, menstrual abnormalities and impotence due to its agonist activity at the progesterone receptor and antagonist activity at the androgen receptor. finerenone is claimed to be a more selective blocker of the mineralocorticoid receptor than spironolactone being associated with fewer antiandrogenic side-effects. in this study, we will compare the efficacy, safety and tolerability of finerenone versus spironolactone in patients with hypertension associated with primary aldosteronism.


Eligibility criteria:
inclusion criteria: * 1.age: 18-75 years old. * 2.history of hypertension, dbp \<120 mmhg, sbp \<180 mmhg. * 3.serum potassium level ≥ 2.5 mmol/l. * 4.primary aldosteronis diagnosed by increased aldosterone renin ratio (arr) \> 30 ng/dl: ng/ml/h, and serum aldosterone levels ≥15 ng / dl, and confirmed by captopril inhibition test. exclusion criteria: * 1. abnormal renal function: serum creatinine ≥ 2 × uln or egfr ≤ 60 ml/(min \* 1.73m2); * 2. abnormal liver function: alt and ast ≤ 2.5 × uln, tbil ≤ 1.5 × uln； * 3. cardiac insufficiency, acute myocardial infarction, stroke or other acute cardiovascular events within 6 months; * 4. take spironolactone, guanethidine or reserpine 30 days before enrollment; * 5. known or suspected tumor; other autoimmune diseases, uncontrolled infectious diseases, serious respiratory, blood and nervous system diseases; * 6. there is a pregnancy plan in pregnancy or 3 months before and after treatment. breast-feeding women; * 7. those who have mental illness, alcohol or drug abuse and cannot cooperate with treatment.

Keywords: primary aldosteronism hypertension finerenone spironolactone treatment
regional anesthesia following pediatric cardiac surgery

Conditions: Atrial Septal Defect; Ventricular Septal Defect; Pain, Procedural

Summary: the purpose of this study is to evaluate pain control following pediatric cardiac surgery with the use of local anesthesia via an ultrasound guided regional anesthetic technique compared with surgeon delivered wound infiltration.

this is a single center, randomized, double blind investigation which will compare postoperative pain control indices, functional recovery metrics and patient/parental satisfaction for pediatric patients receiving an ultrasound guided regional anesthetic versus surgeon delivered wound infiltration in children undergoing primary atrial and ventricular septal defect repairs. surgical and anesthesia care, with the exception of the technique of local anesthetic administration, are not altered for study purposes. subjects are randomized 1:1 to either bilateral pecto-intercostal fascial block and unilateral rectus sheath block or infiltration of the wound through the perioperative period. both interventions will use an equal volume of ropivacaine 0.2% based on weight. exploratory data will be collected for up to 30 days postoperatively.

Eligibility criteria:
inclusion criteria: 1. children less than 18 years old 2. presenting for primary atrial septal defect or ventricular septal defect repair 3. informed consent / assent provided exclusion criteria: 1. patients on opioid therapy at the time of surgery 2. history of sternotomy 3. planned postoperative intubation 4. current diagnosis of a chronic pain syndrome.

Keywords: regional anesthesia
an extension of the tg1101-rms201 trial

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: this study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis


Eligibility criteria:
inclusion criteria: * subjects currently enrolled in tg1101-rms201 trial * subjects who have completed three infusions of ublituximab (at day 1, day 15, and week24, as specified in the tg1101-rms201 protocol) and have completed the scheduled assessments up to the final 48-week visit exclusion criteria: * subjects who discontinued ublituximab treatment or withdrew consent from the tg1101- rms201 study during the 48-week evaluation period * subjects who have started any other immunomodulating or disease modifying therapy after completion of the tg1101-rms201 trial * pregnant or nursing mothers

Keywords: relapsing multiple sclerosis
brain metastasis development mechanism in bcbm patients

Conditions: Breast Cancer; Brain Metastasis

Summary: this study is the experimental study for brain metastasis development mechanism in patients with breast cancer with brain metastasis


Eligibility criteria:
inclusion criteria: * breast cancer * brain metastasis curative surgery patient exclusion criteria: * gamma knife surgery patient
safety and tolerability of intravitreal vegf trap formulations in subjects with neovacular amd

Conditions: Neovascular Age Related Macular Degeneration

Summary: to assess the safety and tolerability of repeated intravitreal (itv) administration of vegf trap.

a double-masked study in which approximately 12 subjects will receive itv injections of vegf trap every 4 weeks for a total of 3 doses. once the subjects have received the 3 doses allowed in this study, they will be evaluated every 4 weeks for continued dosing of vegf trap for an additional 9 months.

Eligibility criteria:
inclusion criteria: * subfoveal cnv secondary to amd. * central retinal (including lesion) thickness ≥ 250 µm as measured by oct. * etdrs best-corrected visual acuity (bcva) of 20/40 to 20/400 (73 to 20 letters) exclusion criteria: * no prior treatment with the following in the study eye: * subfoveal thermal laser therapy; * submacular surgery or other surgical intervention for the treatment of amd; * extrafoveal laser coagulation treatment within 12 weeks prior to day 1 (visit 2); * pdt or itv administration of triamcinolone acetonide or any other steroid within 12 weeks prior to day 1 (visit 2); * pegaptanib sodium within 8 weeks of day 1 (visit 2); * juxtascleral steroids or anecortave acetate within 180 days (6 months) prior to day 1 (visit 2); * prior systemic or intravitreal treatment with vegf trap or bevacizumab; * any investigational agent for the treatment of eye disease within 12 weeks of day 1 (visit 2) * history of any vitreous hemorrhage within 4 weeks prior to baseline injection visit. * aphakia or pseudophakia with the absence of a posterior capsule (unless it occurred as a result of a yttrium aluminum garnet \[yag\] capsulotomy). * significant subfoveal atrophy or scarring. * any condition or laboratory abnormality that, in the opinion of the investigator, would interfere with the assessment of disease status/progression or jeopardize the subject's appropriate participation in this study
modulation of circulating levels of the ketone body 3-hydroxybutyrate in patients with type 2 diabetes and heart failure with preserved ejection fraction: metabolic effects. (keto-hfpef-metabolic)

Conditions: Heart Failure With Preserved Ejection Fraction; Diabetes Mellitus, Type 2; Ketonemia

Summary: heart failure (hf) is among the most common causes of death in patients with type 2 diabetes (t2d). ketones, 3-hydroxybutyrate (3-ohb), have shown to have beneficial effects in patients with hearth failure with reduced ejection fraction. however, this have never been investigated in patients with heart failure with preserved ejection fraction (hfpef). in this study we would like to investigate the effect of 14 days modulation of circulating ketone body levels on whole body and skeletal metabolism in patients with hfpef and t2d.


Eligibility criteria:
inclusion criteria: (i) type 2 diabetes, (ii) lvef \> 40 %, (iii) a clinical diagnosis of hfpef and/or left ventricular hypertrophy (posterior wall thickness \> 12 mm) and/or previous myocardial infarction, (iiii) age ≥ 18 years old, and (iv) one of the following criteria (a-d) should be fulfilled: echocardiographic signs of diastolic dysfunction e/e' \> 8 septal e ́\ 4 cm nt-probnp \> 125 pg/ml. exclusion criteria: * insulin treatment, inability to give informed consent